Trial Profile
A Phase II Study to Evaluate the Performance of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer in Men With an Elevated PSA
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Apr 2023
Price :
$35
*
At a glance
- Drugs Piflufolastat F18 (Primary)
- Indications Prostate cancer
- Focus Diagnostic use
- 10 Apr 2023 Planned End Date changed from 7 Mar 2023 to 7 Mar 2025.
- 10 Apr 2023 Planned primary completion date changed from 7 Mar 2023 to 7 Mar 2025.
- 05 Apr 2022 Planned primary completion date changed from 7 Mar 2022 to 7 Mar 2023.